Search results for "OSA"

showing 10 items of 9388 documents

Diurnal variations in visual performance for disposable contact lenses.

2013

The purpose of this study is to compare the visual performance provided by different daily disposable contact lenses and to analyze its variation over time.Visual performance was evaluated in terms of visual acuity (VA) and contrast sensitivity (CS) in 15 myopic subjects (-0.50 to -4.00 diopters) who had been previously fitted with each one of the following seven types of soft contact lenses: DAILIES TOTAL1 (Alcon, Forth Worth, TX), DAILIES AquaComfort Plus (Alcon), 1-DAY ACUVUE TruEye (JohnsonJohnson Vision Care, Jacksonville, FL), 1-DAY ACUVUE MOIST (JohnsonJohnson Vision Care), SofLens daily disposable (BauschLomb, Rochester, NY), Proclear 1 Day (CooperVision, Fairport, NY), and Clariti …

AdultMaleVisual acuitygenetic structuresmedia_common.quotation_subjectVisual AcuityContrast SensitivityYoung AdultmedicineMyopiaContrast (vision)HumansDisposable EquipmentVision Ocularmedia_commonMathematicsContact Lenses Hydrophiliceye diseasesCircadian RhythmOphthalmologyOptometryDaily disposableFemalesense organsDisposable Equipmentmedicine.symptomOptometryOptometry and vision science : official publication of the American Academy of Optometry
researchProduct

The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

2013

Abstract Objectives The objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects. Methods MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels. Results Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean ± SD height z-scores were − 5.6 ± 3.1 as determined by the CDC growth charts. Mean ± SD from the 6-minute-walk-test was 212.6 ± 152.2 m, revealing limitation…

AdultMaleVital capacitymedicine.medical_specialtyAdolescentCross-sectional studyEndocrinology Diabetes and MetabolismMucopolysaccharidosisMotor ActivityBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyElosulfase alfaQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingGeneticsmedicineHumansMedical historyRespiratory functionChildExerciseMolecular BiologyGlycosaminoglycans030304 developmental biology0303 health sciencesbusiness.industryInfant NewbornInfantMucopolysaccharidosis IVmedicine.diseaseUnited StatesRespiratory Function TestsCross-Sectional StudieschemistryKeratan SulfateChild PreschoolPhysical EnduranceQuality of LifeMucopolysaccharidosis IVPhysical therapyFemalebusiness030217 neurology & neurosurgeryMolecular Genetics and Metabolism
researchProduct

Normal intestinal dietary fat and cholesterol absorption, intestinal apolipoprotein B (ApoB) mRNA levels, and ApoB-48 synthesis in a hypobetalipoprot…

1997

Abstract The purpose of this study was to characterize intestinal apolipoprotein B (apoB) metabolism in subjects with familial hypobetalipoproteinemia (FHBL), where segregation analysis supports linkage to the apoB gene but no apoB truncations are present. We investigated cholesterol and fat absorption, intestinal apoB mRNA synthesis and editing, as well as apoB-48 synthesis. Plasma triglycerides (TG) and retinyl palmitate in the chylomicron fractions were analyzed after 12 hours of fasting and then repeatedly for 14 hours after ingestion of a vitamin A—containing high-fat meal. Cholesterol absorption was assessed using a dual stable-isotope method. Mean peak times and concentrations and ar…

AdultMaleVitaminmedicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and Metabolismdigestive systemAbsorptionCholesterol DietaryHypobetalipoproteinemiasEatingchemistry.chemical_compoundEndocrinologyInternal medicineRetinyl palmitatemedicineHumansRNA MessengerIntestinal MucosaHypoalphalipoproteinemiaAgedApolipoproteins BMethioninebiologyCholesterolnutritional and metabolic diseasesNuclease protection assayMiddle Agedmedicine.diseaseDietary FatsLipidsEndocrinologychemistrybiology.proteinFemalelipids (amino acids peptides and proteins)RNA EditingApolipoprotein B-48ChylomicronMetabolism
researchProduct

Methodological Aspects of the Application of the Naka-Rushton Equation to Clinical Electroretinogram

1993

The nonlinear relation between stimulus intensity and response amplitude of the electroretinogram (ERG) scotopic b wave can be described by a curve based on the Naka-Rushton (NR) equation. Up to now, the NR equation has been used to assess the features of the normal and pathological ERG, but the best approach for a correct evaluation of the parameters is still debatable. The parameters are thought to be related to the different conditions of retinal activities. The method is well known in experimental laboratories but is quite unusual at the clinical level. In the present paper the derivative analysis of the NR function is proposed as an easier approach to understand the variations of the N…

AdultMaleX ChromosomeAdolescentLightElectrodiagnosisGenetic LinkageVisual AcuityDark AdaptationCataractRetinaCellular and Molecular NeuroscienceExperimental LaboratoriesOpticsRetinal DiseasesElectroretinographymedicineHumansResponse AmplitudeApplied mathematicsScotopic visionChildAgedMathematicsmedicine.diagnostic_testbusiness.industryDerivative analysisGeneral MedicineMiddle AgedSensory SystemsOphthalmologyFemalebusinessRetinitis PigmentosaElectroretinographyOphthalmic Research
researchProduct

Production of Anti-Endomysial Antibodies in Cultured Duodenal Mucosa: Usefulness in Coeliac Disease Diagnosis

2002

Although anti-endomysial antibodies (EmA) have been found in the supernatants of cultured intestinal mucosa from patients with coeliac disease (CD), in no study has the clinical reliability of this new diagnostic tool been investigated. Our aims were to evaluate the clinical usefulness of the in vitro production of EmA in CD diagnosis in consecutive patients with suspected CD, and to evaluate the reliability of the in vitro challenge in CD patients on a gluten-free diet (GFD).For the former aim, consecutive patients who were due to undergo intestinal biopsy for suspected diagnosis of CD were enrolled: according to the final diagnosis, these patients were divided into two groups: Group 1 com…

AdultMaleanti-endomysial antibodiemedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentDuodenumIn Vitro TechniquesSensitivity and SpecificityGastroenterologyGliadinCoeliac diseaseIntestinal mucosaImmunopathologyInternal medicineSuspected diagnosisHumansMedicineChildCells CulturedAgedbiologybusiness.industryGastroenterologyInfantReproducibility of ResultsMiddle Agedcultured duodenal mucosa: coeliac disease diagnosismedicine.diseaseAntibodies Anti-IdiotypicCeliac Diseasemedicine.anatomical_structureGastric MucosaChild PreschoolAntibody FormationDuodenumbiology.proteinDuodenal mucosaFemaleHistopathologyAntibodycoeliac disease diagnosis [anti-endomysial antibodies; cultured duodenal mucosa]businessScandinavian Journal of Gastroenterology
researchProduct

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain

2007

The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was performed in 25 cancer patients receiving stable opioid doses. For each episode, when it occurred and 15 and 30 min after the treatment, pain intensity and opioid-related symptoms were recorded. Fifty-three couples of breakthrough events, each treated with IV-MO and OTFC, were recorded. In episodes treated with IV-MO, pain intensity decreased from a mean of 6.9 to 3.3 and to 1.7 at T1 and T2, respectively. In episodes treated with OTFC, pain int…

AdultMalecancer painCancer Researchintravenous morphineAdolescentTransmucosal fentanyl; intravenous morphine; episodic-breakthrough pain.Transmucosal fentanylAdministration OralPainFentanylNeoplasmsClinical StudiesmedicineHumansDosingChildOTFCAdverse effectCross-Over StudiesMorphinebusiness.industryInfantopioidsMiddle Agedbreakthrough painCrossover studyAnalgesics OpioidFentanylRegimenepisodic-breakthrough pain.OncologyOpioidChild PreschoolAnesthesiaInjections IntravenousMorphineFemalebusinessCancer painmedicine.drugBritish Journal of Cancer
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

Nitric oxide metabolites and erythrocyte deformability in a group of subjects with obstructive sleep apnea syndrome

2014

Our aim was to evaluate nitric oxide metabolites (nitrite and nitrate), expressed as NOx, and erythrocyte deformability, expressed as elongation index, in a group of subjects with obstructive sleep apnea syndrome (OSAS). We enrolled 48 subjects (36 men and 12 women; mean age 50.3 ± 14.68 yrs) with OSAS diagnosed after a 1-night cardiorespiratory sleep study. OSAS severity was assessed evaluating the apnea/hypopnea index (AHI) and subjects were subdivided in two subgroups: Low (L = AHI 30). NOx was examined converting nitrate into nitrite with a nitrate reductase and then assessing nitrite with spectrophotometry after the addition of Griess reagent. The elongation index was obtained using th…

AdultMaleerythrocyte deformabilitymedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyNOxNitric OxideNitric oxidechemistry.chemical_compoundstomatognathic systemGriess testPhysiology (medical)Internal medicinemedicineHumansErythrocyte deformabilitySleep studyNitriteNitritesAgedSleep Apnea ObstructiveNitratesbusiness.industryApneaOSASHematologyMiddle Agedmedicine.diseaserespiratory tract diseasesSurgeryObstructive sleep apneaEndocrinologychemistryblood rheology nitric oxide metabolism laser diffractometryFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessHypopnea
researchProduct

High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.

2015

Naringin is considered the major causative ingredient of the inhibition of intestinal drug uptake by grapefruit juice. Moreover, it is contained in highly dosed nutraceuticals available on the market. A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake. Following 6-day supplementation with 3 capsules of 350 mg naringin daily, 100mg talinolol were administered orally with 3 capsules of the same dietary supplement (1050 mg naringin) on the seventh day. This test treatment was compared to …

AdultMalefood.ingredientAdrenergic beta-AntagonistsPharmaceutical ScienceOrganic Anion TransportersPharmacologyPolymorphism Single NucleotideDosage formGrapefruit juicePropanolamineschemistry.chemical_compoundFood-Drug InteractionsYoung AdultNutraceuticalfoodPharmacokineticsHumansNaringinDosage FormsCross-Over StudiesDose-Response Relationship DrugChemistryCrossover studyBioavailabilityDietary SupplementsFlavanonesFemaleTalinololCitrus paradisiEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.

2018

Aims Aim of this study was to associate concentration of naltrexone and its major active metabolite 6β-naltrexol in blood with therapeutic outcome during treatment with naltrexone in subjects with alcohol dependence. Treatment with the μ-opiate receptor antagonist naltrexone has been shown to reduce craving for alcohol and alcohol intake in patients suffering from alcohol dependence. Short summary This article shows the use of therapeutic drug monitoring in alcohol dependent patients, who are treated with naltrexone. The plasma concentrations of naltrexone and 6β-naltrexol showed high inter-individual variability. They were predictive for treatment response, as they correlated significantly…

AdultMalemedicine.drug_classAcamprosateNarcotic Antagonists030508 substance abuseCravingAlcoholPharmacologyNaltrexone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodReference ValuesmedicineHumansActive metaboliteCravingEthanolmedicine.diagnostic_testbusiness.industryAlcohol dependenceGeneral MedicineMiddle AgedReceptor antagonistNaltrexoneAlcoholismTreatment OutcomechemistryTherapeutic drug monitoringDrug Therapy CombinationFemalemedicine.symptomDrug Monitoring0305 other medical sciencebusiness030217 neurology & neurosurgerymedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct